Actively Recruiting
A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC
Led by Qilu Pharmaceutical Co., Ltd. · Updated on 2025-06-10
808
Participants Needed
1
Research Sites
97 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to compare the efficacy similarities between QL2107 and Keytruda in metastatic non-squamous NSCLC.
CONDITIONS
Official Title
A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years
- Voluntarily agree to participate and able to follow study procedures
- Confirmed metastatic (stage IV) non-squamous NSCLC according to AJCC 8th Edition
- No EGFR sensitive mutations or ALK gene translocations
- Expected survival of at least 3 months
- ECOG performance status score of 0 or 1
You will not qualify if you...
- Pulmonary radiation therapy greater than 30 Gy within 6 months before first dose
- Palliative radiation therapy completed within 7 days before first dose
- Need for any other anti-tumor therapy during the study
- Uncontrolled or symptomatic pericardial effusion, pleural effusion, or ascites requiring repeated drainage
- Brain stem, meninges, or spinal cord metastases or compression
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shandong First Medical University Cancer Hospital
Jinan, Shandong, China
Actively Recruiting
Research Team
J
Jinming Yu, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here